Maze Therapeutics, Inc. Common Stock

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1 (APOL1) in Phase II for APOL1 kidney disease, and MZE782, an oral small molecule inhibitor in Phase II-ready development for phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase for Pompe disease. It has license agreements with Trace Neuroscience, Inc. for a discovery research program targeting UNC13A; Shionogi & Co., Ltd. to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. for a discovery research program targeting ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. It was incorporated in 2017 and is based in South San Francisco, California.

MAZE▼2

Maze Therapeutics CEO Jason Coloma Sold Nearly 30,000 Shares Under Prearranged Trading Plan

Maze Therapeutics CEO Jason Coloma sold 27,858 shares indirectly for approximately $725,000 across June 22 and June 23, 2026, under a prearranged Rule 10b5-1 trading plan adopted in February 2026. The sales reduced his indirect holdings from 372,867 to 345,009 shares, with all shares held through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust. The average transaction price was around $26.04 per share, while the stock closed at $26.41 on June 23, up 134.38% over the past year. Coloma retained over 300,000 shares indirectly, and the company ended the first quarter with $362.9 million in cash, expected to fund operations into 2029 as it advances Phase 2 trials for kidney and metabolic disease therapies.

MAZE ▼

The Motley Fool·81dRead more →